Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used
/in Dendritic Cells, International Publications, Malignant MelanomaDurable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy
/in Breast Cancer, Hyperthermia, International PublicationsCombination of ionising irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells
/in Colorectal Cancer, Hyperthermia, International PublicationsNADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment
/in Hyperthermia, International PublicationsDendritic cell-based immunotherapy for prostate cancer
/in Dendritic Cells, International Publications, Prostate CancerTherapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer
/in International Publications, Newcastle Disease Virus[WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers]
/in Dendritic Cells, Esophageal Carcinoma, International PublicationsPalliation of recurrent myxofibrosarcoma with radiotherapy and hyperthermia
/in Hyperthermia, International Publications, Soft Tissue SarcomaGenetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
/in Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer